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lower GI tract: an underestimate of adverse events of
conventional NSAIDs?
Based on previous trials comparing a co-prescription of tradi-
tional NSAIDs plus proton-pump inhibitor (PPI) and cyclo-
oxygenase-2 (COX-2) selective drugs, the risk of having an upper
gastrointestinal (GI) event (ulcer, perforation, bleeding and
obstruction) is similar in between both groups. However, the risk of
lower GI events has never been assessed in a randomized
controlled trial. In this study [named CONDOR for “Celecoxib vs
omeprazole and diclofenac in patients with osteoarthritis (OA) and
rheumatoid arthritis (RA)”], the authors performed a 6-month,
double-blind, multicenter randomized controlled trial in patients at
increased GI risk (deﬁned by an age over 60 or over 18 with
a history of a previous gastro-duodenal ulceration) with OA or RA in
order to compare the risk of GI events, upper and lower, associated
with celecoxib 200 mg bis in die meaning two times a day (BID) vs
diclofenac slow release 75 mg BID plus omeprazole 20 mg once
a day1. Patients needing low-dose aspirin were excluded. The
primary endpoint was a composite of upper and lower events
including hamorrhage from deﬁned or undeﬁned origin, small
bowel or large bowel perforation, gastric obstruction, clinically
signiﬁcant anemia deﬁned by a decrease of 20 g/L or more, or
a decrease in hematocrit of at least 10 percentage points (Table I)2.
Among 4,484 patients randomly allocated to treatment (assigned in
a 1:1 ratio), 0.9% patients receiving celecoxib and 3.8% receiving
diclofenac plus omeprazole met criteria for the primary endpointF. Berenbaum, Pierre & Marie
, France. Tel: 33-149282520;
Elsevier Ltd on behalf of Osteoart[Hazard ratio (HR) ¼ 4.3, 95% credible interval (CI) 2.6e7.0,
P < 0.0001] (Fig. 1). Interestingly, the main reason for this differ-
ence was due to a major increase in signiﬁcant anemia from
unknown origin in the diclofenac plus omeprazole group (53/2246)
vs the celecoxib group (10/2238). Based on the results of this study,
the authors consider that COX-2 selective NSAIDs would be less
deleterious for the lower GI tract than conventional NSAIDs þ PPI
maybe due to an absence of protection of PPI on NSAIDs-induced
small bowel and colon mucosa lesions. The main question raised by
this study is the clinical signiﬁcance of a loss of 20 g/L hemoglobin,
the main impressive difference between both groups. One can
argue that another arbitrary threshold would perhaps lead to
different conclusions. Moreover, the results of this study cannot be
extrapolated to the large population of patients treated with anti-
aggregants like aspirin, meaning that the potential beneﬁt of COX-2
selective agents over conventional NSAIDs on lower GI tract in
patients at increased risk for GI events could be challenged by an
increased risk, even controversial, of cardiovascular (CV) events in
these patients. Even with these limitations, the NSAIDs-induced
lower GI tract toxicity should now be taken into account for the
assessment of the beneﬁt-risk balance of NSAIDs. Finally, another
critical interest of this study is to highlight an underestimate of
adverse events of conventional NSAIDs, that is the NSAIDs-induced
lower GI tract outcome.Glucosamine and chondroitin: to be or not to be effective?
For decades, the pros and cons debate on the efﬁcacy of
glucosamine and chondroitin for the treatment of OA symptoms
and joint degradation. Pros consider that there are nowenough data
in the literature to prove that these natural cartilage components do
have a signiﬁcant effect at least on pain and function and maybe on
delaying OA cartilage degradation based on X-ray databases. Sincehritis Research Society International.
Table I
The composite primary endpoint used in the CONDOR trial (simpliﬁed from2)
With lesion Without lesion
GD hemorrhage: endoscopic
evidence of GD ulceration or
erosion or other likely causative
lesion, and clinical evidence
of recent hemorrhage.
Gastric outlet obstruction.
GD, small bowel, or large
bowel perforation.
Large bowel hemorrhage:
frank melena or PR blood loss
with no evidence of source on
EGD and likely causative lesion
on colonoscopy.
Small bowel hemorrhage: frank
melena or PR blood loss with likely
causative lesion on small bowel
investigation.
Small bowel obstruction.
Clinically signiﬁcant anemia of
deﬁned GI origin: no clinical
evidence of acute GI hemorrhage
but with fall in Hct  10% points
and/or Hgb  2 g/dl from
baseline, with likely causative
lesion on colonoscopy or EGD
(or small bowel investigation)
with no non-GI source of anemia,
and, in RA patients, disease
activity should be stable.
Symptomatic ulcers: cases that
do not meet the deﬁnition of an
ulcer complication but do have
endoscopic evidence of a gastric
and/or duodenal ulcer, as
adjudicated by the GI events
committee.
Acute GI hemorrhage of
unknown origin, including
presumed small bowel
hemorrhage: rank hematemesis,
melena, or PR blood loss, with
no evidence of likely causative
lesion on EGD or colonoscopy
(or small bowel investigation).
Clinically signiﬁcant anemia of
presumed occult GI origin,
including possible small bowel
blood loss: no overt clinical
evidence of acute GI hemorrhage
but with fall in Hct  110%
points and/or Hgb  2 g/dl from
baseline, with no evidence of
likely causative lesion on EGD or
colonoscopy (or small bowel
investigation) with no non-GI
source of anemia identiﬁed, and,
in RA patients, disease activity
should be stable.
Abbreviations: GD ¼ gastroduodenal, Hgb ¼ hemoglobin, Hct ¼ hematocrit,
EGD ¼ esophagogastroduodenoscopy.
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would be in favor of prescribing them in order to decrease the
number of prescriptions of analgesics/anti-inﬂammatory drugs,
muchmore toxic. On the other hands, Cons consider that the quality
of the published studies is questionable, and raise concerns about
potential conﬂicts of interest in some of them. Moreover, they
challenge the clinical signiﬁcance of these small effect-sizes seen in
these studies, and could be even lower due to a number of unpub-
lished negative trials. This year, one study brought more fuel to the
cons’ ﬁre3. It is a network meta-analysis looking at the effects of
glucosamine, chondroitin, or placebo in hip and knee OA patients. A
network meta-analysis is a direct comparison within trials
combined with indirect evidence from other trials by using
a Bayesianmodel that allowed the synthesis ofmultiple time points.
This sophisticated analysis allows a comparison either of these
preparations with placebo or head to head. The main outcome
measure was pain intensity whereas the secondary outcome was
the change in minimal width of joint space. The minimal clinically
important difference between preparations and placebo was pre-
speciﬁed at 0.9 cm on a 10 cm visual analog scale (VAS). The
sources of the data were electronic databases and conference
proceedings from inception to June 2009, expert contact, and rele-
vant websites. Only large scale randomized controlled trials inmore
than 200 patients with hip or knee OA that compared glucosamine,
chondroitin, or their combinationwith placebo or head to headwere
selected. Ten trials in 3,803 patients were included. On a 10 cm VAS
the overall difference in pain intensity compared with placebo was0.4 cm (95% CI0.7 to0.1 cm) for glucosamine,0.3 cm (0.7 to
0.0 cm) for chondroitin, and 0.5 cm (0.9 to 0.0 cm) for the
combination (Fig. 2). For none of the estimates did the 95% CIs cross
the boundary of the minimal clinically important difference.
Industry independent trials showed smaller effects than commer-
cially funded trials (P ¼ 0.02 for interaction). The differences in
changes in minimal width of joint space were all minute, with 95%
CIs overlapping zero. The authors conclude that compared with
placebo, glucosamine, chondroitin, and their combination do not
reduce joint pain or have an impact on narrowing of joint space. Of
course, as in any studies, some weaknesses could lead to misinter-
pretations. For example, the selection of randomized trials having
on average at least 100 subjects in each treatment arm could be
debated even if this choice relies upon previous analysis showing
that small studies, with fewer than 100 patients/treatment arm, are
prone to numerous methodological deﬁciencies and reporting bia-
ses4. Another point of discussion is the type of methodology which
leads to an absence of comparison like to like as in conventional
meta-analysis. Finally, for the pros, the fact that these supplements
have a very small effect in several trials does notmean that it should
not be part of the arsenal for treating OA since this effect-size is very
similar or identical to what is seen with acetaminophen with
a better safety proﬁle. So, the discussion is not closed and we can
expect that it will go on in 2011..
The ﬁrst biotherapy for knee and hip OA: life.and death of
tanezumab?
A few months ago, a phase II trial with an antibody raised
against the Nerve Growth Factor (NGF) called tanezumab, pub-
lished in the New England Journal of Medicine, unchained
enthusiasm since it opened the ﬁrst opportunity for a biotherapy
in OA5. This proof-of-concept trial was based on preclinical studies
showing that NGF regulates the structure and function of
responsive sensory neurons, including small-diameter nociceptive
afferents. Lane et al. randomly assigned 450 patients with OA of
the knee to receive tanezumab (administered at a dose of 10, 25,
50, 100, or 200 mg/kg of body weight) or placebo on days 1 and 56.
The primary efﬁcacy measures were knee pain while walking and
the patient’s global assessment of response to therapy. They also
assessed pain, stiffness, and physical function using the WOMAC,
the rate of response using the OMERACTeOARSI criteria and
safety. When averaged over weeks 1 through 16, the mean
reductions from baseline in knee pain while walking ranged from
45% to 62% with various doses of tanezumab, as compared with
22% with placebo (P < 0.001) (Fig. 3). Tanezumab, as compared
with placebo, was also associated with signiﬁcantly greater
improvements in the response to therapy as assessed with the use
of the patients’ global assessment measure (mean increases in
score of 29e47% with various doses of tanezumab, as compared
with 19% with placebo; P  0.001). The rate of response according
to the OMERACTeOARSI criteria ranged from 74% to 93% with
tanezumab treatment, as compared with 44% with placebo
(P < 0.001). However, these impressive results in term of efﬁcacy
(higher than usually seen with an NSAID) have to be challenged
with the neurological side effects seen in all the studies per-
formed with tanezumab: one of the most common adverse events
among tanezumab-treated patients was paresthesia (7% in the
Lane’s study). A pivotal phase III trial in knee OA has been pre-
sented at the last 2010 European League Against Rheumatism
(EULAR) meeting6 and a phase III trial in hip OA has been
extensively presented at the last 2010 American College of
Rheumatology (ACR) meeting7: both studies conﬁrmed the results
of the previous phase II knee OA study (although less impressive
in term of efﬁcacy), also in term of the neurological safety issue.
Fig. 1. Cumulative proportion of patients with adjudicated clinically signiﬁcant events throughout the GI tract. Proportion of patients with the primary endpoint was estimated on
the basis of the cox-proportional model. [Reprinted from The Lancet, Vol 376, Chan FKL, Lanas A., Scheiman J., Berger MF, Nguyen H., Goldstein JL. Celecoxib vs omeprazole and
diclofenac in patients with OA and RA (CONDOR): a randomised trial. pp. 173e179., Copyright 2011, with permission from Elsevier].
Fig. 2. Differences in pain intensity measured on VAS between experimental interventions and placebo over time. Shading represents area of clinical equivalence. Negative values
indicate beneﬁt of experimental interventions compared with placebo. (Reprinted from BMJ 341:doi:10.1136/bmj.c4675. Wandel S, Jüni P, Tendal B, Nüesch E, Villiger PM, Welton NJ,
Reichenbach S, Trelle S. Effects of glucosamine, chondroitin, or placebo in patients with OA of hip or knee: network meta-analysis. Copyright 2011, with permission from BMJ).
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Fig. 3. Patients’ assessment of pain while walking. The patient’s assessment of knee pain while walking were obtained at baseline and at the indicated times with the use of a visual
analogue scale that ranged from 0 to 100. In the case of knee pain, a decrease in the score indicates improvement (i.e., less pain). Changes are reported as least-squares
means  standard error (SE). P < 0.001 for the comparisons of all doses of tanezumab with placebo in the assessment of knee pain (Copyright 2011, with permission from the
New England Journal of Medicine).
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mab were halted by Food and Drug Administration (FDA) because
of an unexpected increase of joint prosthesis in the tanezumab
group compared to the placebo group. There are several tentative
explanations for such events such as drug-induced osteonecrosis,
accelerated OA due to joint overuse, although it could also be only
due to chance. The reading of each clinical case is under review at
the FDA and conclusions on the responsibilities of the drug are
expected in mid-2011.
Targeted therapies: the future for the pharmacological
treatment of OA
By reviewing the ongoing trials testing the proof-of-concept of
targeted therapies, deﬁned as drugs speciﬁcally designed to inter-
ferewith a speciﬁc point in the pathogenesis of OA, it seems that we
can be more optimistic for the next decade compared to the
previous one8. Although the ﬁrst targeted biotherapy, tanezumab,
is halted in its development, other molecules like drugs targeting
the subchondral bone (calcitonin, strontium ranelate) or anti-
cytokines (anti-IL-1, anti-Tumor Necrosis Factor (TNF), anti-IL-6.)
could open new perspectives in this ﬁeld. Some signals already
exist in the literature like this recent one published in 2010: Güler-
Yüksel et al. have looked at the effect of inﬂiximab, an antibody
raised against TNFa, in patients included in the Best study, a well-
known ongoing multicenter, randomized clinical trial designed to
compare the efﬁcacy of four treatment strategies in recent-onset
active RA patients9. The authors scored hand X-rays for OA and
compared the effect of inﬂiximab to other disease-modifying anti-
rheumatic drugs. Interestingly, treatment with inﬂiximab was
associated with less incident secondary OA in proximal interpha-
langeal joints, (6% vs 13%, P ¼ 0.059). Five patients treated with
inﬂiximab (24%) had progressive secondary OA in proximal inter-
phalangeal joints vs 14 (42%) of the patients not treated with
inﬂiximab (P ¼ 0.163). In multivariable analyses, adjusted for age,
gender, menopausal status, Body Mass Index (BMI), inﬂammatorysymptom duration, OA at baseline and the use of anti-resorptive
treatment during the study period, treatment with inﬂiximab
showed a trend toward less incident secondary OA in proximal
interphalangeal joints with an RR (95% CI) of 0.5 (0.2, 1.1)
(P ¼ 0.087).
In conclusion, big pharma, alongwith biotechnology companies,
are in the starting block for the development of the next decade’s
blockbusters, for symptoms and for structure.
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